{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:11:31Z","timestamp":1773277891978,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.4158\/ep09148.rar","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T21:06:42Z","timestamp":1245704802000},"page":"597-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm"],"prefix":"10.1016","volume":"15","author":[{"given":"Lei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libero","family":"Santarpia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP09148.RAR_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies","volume":"16","author":"Smallridge","year":"2009","journal-title":"Endocr Relat Cancer."},{"key":"10.4158\/EP09148.RAR_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.soc.2006.05.005","article-title":"Adrenocortical carcinoma","volume":"15","author":"Rodgers","year":"2006","journal-title":"Surg Oncol Clin N Am."},{"key":"10.4158\/EP09148.RAR_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine","volume":"83","author":"Nocera","year":"2000","journal-title":"Br J Cancer"},{"key":"10.4158\/EP09148.RAR_bb0020","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H","article-title":"Phase I\/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma","volume":"85","author":"Juweid","year":"1999","journal-title":"Cancer."},{"key":"10.4158\/EP09148.RAR_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ecl.2008.03.001","article-title":"Management of medullary thyroid carcinoma","volume":"37","author":"Jim\u00e9nez","year":"2008","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP09148.RAR_bb0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev."},{"key":"10.4158\/EP09148.RAR_bb0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature."},{"key":"10.4158\/EP09148.RAR_bb0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2a and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet."},{"key":"10.4158\/EP09148.RAR_bb0045","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1056\/NEJMe038148","article-title":"Lessons learned from the management of a rare genetic cancer","volume":"349","author":"Cote","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP09148.RAR_bb0050","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ncponc0610","article-title":"Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy","volume":"3","author":"Drosten","year":"2006","journal-title":"Nat Clin Pract Oncol."},{"key":"10.4158\/EP09148.RAR_bb0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcrabl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science."},{"key":"10.4158\/EP09148.RAR_bb0060","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al (International STI571 CML Study Group). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia [published correction appears in N Engl J Med . 2002;346:1923]. N Engl J Med . 2002;346: 645-652.","DOI":"10.1056\/NEJMoa011573"},{"issue":"suppl 1","key":"10.4158\/EP09148.RAR_bb0065","first-page":"28","article-title":"Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec)","volume":"97","author":"Joensuu","year":"2002","journal-title":"Med Klin (Munich)."},{"key":"10.4158\/EP09148.RAR_bb0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med."},{"key":"10.4158\/EP09148.RAR_bb0075","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1038\/sj.onc.1204704","article-title":"STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications","volume":"20","author":"Tuveson","year":"2001","journal-title":"Oncogene."},{"key":"10.4158\/EP09148.RAR_bb0080","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med."},{"key":"10.4158\/EP09148.RAR_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"(European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.4158\/EP09148.RAR_bb0090","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.4158\/EP09148.RAR_bb0095","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res."},{"key":"10.4158\/EP09148.RAR_bb0100","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res."},{"key":"10.4158\/EP09148.RAR_bb0105","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"issue":"18 (suppl)","key":"10.4158\/EP09148.RAR_bb0110","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/jco.2006.24.18_suppl.5533","article-title":"A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer [abstract]","volume":"24","author":"Wells","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 (suppl)","key":"10.4158\/EP09148.RAR_bb0115","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1200\/jco.2007.25.18_suppl.6018","article-title":"Vandetanib in metastatic hereditary medullary thyroid cancer: followup results of an open-label phase II trial [abstract]","volume":"25","author":"Wells","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15 (suppl)","key":"10.4158\/EP09148.RAR_bb0120","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/jco.2008.26.15_suppl.3522","article-title":"A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) [abstract]","volume":"26","author":"Salgia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP09148.RAR_bb0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst."},{"key":"10.4158\/EP09148.RAR_bb0130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-07-2422","article-title":"Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib\/tipifarnib","volume":"7","author":"Hong","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"10.4158\/EP09148.RAR_bb0135","series-title":"A phase II study of sorafenib in patients with metastatic medullary thyroid carcinoma. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; April 18-22","first-page":"4513","author":"Lam","year":"2009"},{"key":"10.4158\/EP09148.RAR_bb0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann Intern Med."},{"issue":"15 (suppl)","key":"10.4158\/EP09148.RAR_bb0145","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1200\/jco.2009.27.15_suppl.6056","article-title":"Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC) [abstract]","volume":"27","author":"Carr","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP09148.RAR_bb0150","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet."},{"key":"10.4158\/EP09148.RAR_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"(Motesanib Thyroid Cancer Study Group). Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med."},{"key":"10.4158\/EP09148.RAR_bb0160","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefi- tinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med."},{"issue":"18, pt 1","key":"10.4158\/EP09148.RAR_bb0165","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1158\/1078-0432.CCR-06-0858","article-title":"Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors","volume":"13","author":"Desai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP09148.RAR_bb0170","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1158\/1078-0432.CCR-06-1745","article-title":"C-Kit\/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors","volume":"13","author":"Miselli","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.4158\/EP09148.RAR_bb0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.beem.2008.09.012","article-title":"Receptor tyrosine kinase inhibitors in thyroid cancer","volume":"22","author":"Castellone","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"10.4158\/EP09148.RAR_bb0180","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP09148.RAR_bb0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant para- ganglioma\/pheochromocytoma","volume":"94","author":"Joshua","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP09148.RAR_bb0190","doi-asserted-by":"crossref","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) [published online ahead of print May 7, 2009]. Horm Metab Res. doi:https:\/\/doi.org\/10.1055\/s-0029-1220687.","DOI":"10.1055\/s-0029-1220687"},{"key":"10.4158\/EP09148.RAR_bb0195","doi-asserted-by":"crossref","unstructured":"Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study [published correction appears in J Clin Oncol. 2008;26:5660]. J Clin Oncol. 2008;26:4311-4318.","DOI":"10.1200\/JCO.2008.16.7858"},{"key":"10.4158\/EP09148.RAR_bb0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","article-title":"The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells","volume":"85","author":"Zitzmann","year":"2007","journal-title":"Neuroendocrinology."},{"key":"10.4158\/EP09148.RAR_bb0205","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4158\/EP.14.5.618","article-title":"Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target","volume":"14","author":"Vetter","year":"2008","journal-title":"Endocr Pract."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20413734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20413734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/CK45R47402P13169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:33Z","timestamp":1761515433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20413734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1530891X20413734"],"URL":"https:\/\/doi.org\/10.4158\/ep09148.rar","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09148.RAR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}